This disclosure describes how to prevent, treat, and cure illness through the use of denaturing agents.

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of K+/Cl-cotransporter (Kcc2/KCC2) gene expression enhancer to a subject in need.

The present disclosure describes, in part, compositions and methods for treating pathologic pains associated with malignant growth disorders by administering a therapeutically effective amount of K+/Cl-cotransporter (Kcc2/KCC2) gene expression enhancer to a subject in need.

Topical formulations of L-ascorbic acid dissolved in a combination of a urea agent and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, are have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. The topical formulations can include cinnamic acid or derivatives thereof as a penetration enhancer and stabilizing component of ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

Topical formulations of L-ascorbic acid dissolved in a combination of a urea agent and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, are have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. The topical formulations can include cinnamic acid or derivatives thereof as a penetration enhancer and stabilizing component of ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

Topical formulations of L-ascorbic acid dissolved in a combination of a urea agent and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, are have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. The topical formulations can include cinnamic acid or derivatives thereof as a penetration enhancer and stabilizing component of ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

The present invention relates to a pharmaceutical composition for treating cancer comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, has an excellent anticancer effect and safety as compared to a conventional case of single administration of an anticancer virus or combined administration of an anticancer virus and an immune checkpoint inhibitor. Accordingly, the pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, may be effectively used in treating cancer.

The present invention relates to a pharmaceutical composition for treating cancer comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, has an excellent anticancer effect and safety as compared to a conventional case of single administration of an anticancer virus or combined administration of an anticancer virus and an immune checkpoint inhibitor. Accordingly, the pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, may be effectively used in treating cancer.